Primate lentiviruses encode a number of auxiliary proteins which are not absolutely necessary for growth in vitro but are essential for viral replication and pathogenicity in vivo (for reviews, see references 15, 18, 43, and 44) . One of these, termed Vif, has long been known to represent an important determinant of viral infectivity, particularly in natural target cells (10, 12, 13, 23, 36, 37, 39, 42) . The HIV-1 vif gene is expressed in vitro (3) and in vivo (21, 26) , and its reading frame has been found intact in the majority of proviruses characterized directly in primary (uncultured) patient tissue (40, 46) . This finding, along with its conservation in the genome of most lentiviruses (30) , including all known primate lentiviruses (18) , strongly suggests an important role for Vif in lentiviral biology. Numerous studies have reported an influence of Vif on the replicative capacity of human and simian immunodeficiency viruses (HIV and SIV) in various target cells. Vif is known to increase viral infectivity, although the magnitude of this effect is dependent on the cell type that is producing the virus (5, 8, 12, 32, 33, 36, 41, 45) . For example, Vif is absolutely required for virus growth in peripheral blood lymphocytes and macrophages (1, 6, 8, 12, 13, 45) . By contrast, established T-cell lines vary in the ability to support replication of vif-deficient mutants (5, 12, 36) . Cell lines have been classified as nonpermissive (e.g., H9) if they require Vif to support HIV type 1 (HIV-1) replication, semipermissive (e.g., SupT1 and CEMx174) if they allow replication of vif-deficient HIV-1 at intermediate levels, and permissive (e.g., HeLa, COS, and C8166) if they replicate vif-deficient HIV-1 to wild-type levels (5) . The existence of cell types that support a productive infection of vif-deficient viruses suggests that Vif can be complemented by (or eliminates the negative effect of) certain cellular factors.
Although the precise mechanism of Vif action remains unknown, current evidence suggests that Vif acts late in the replication cycle at the time of particle formation. When produced from permissive cells, Vif-minus virions are able to enter new target cells (including nonpermissive ones) efficiently, complete proviral DNA synthesis, integrate into the host cell genome, express wild-type amounts of genomic and subgenomic messages, and produce normal quantities of progeny virions (6) . In contrast, when produced from nonpermissive cells, Vif-minus virions have an abnormal protein profile (5, 36) and altered ultrastructural morphology (5, 19) and are severely impaired in the ability to synthesize proviral DNA upon infection of new target cells (5, 41, 45) . Vif-dependent loss of infectivity can be rescued by expression of Vif protein in trans (4, 45) . However, for successful complementation to occur, Vif must be expressed in the producer cell rather than the target cell (45) . Finally, Vif protein has been reported to associate with the cytoplasmic side of cellular membranes, suggesting a role at the cell surface during particle formation (16) . In the absence of evidence indicating Vif incorporation into virions (37, 45) , these data have been interpreted to indicate that Vif is required for the proper incorporation, processing, and/or assembly of virion proteins and thus influences virus infectivity only indirectly.
The experimental basis for concluding that Vif is not associated with HIV or SIV particles derives from only few studies (37, 45) . More recently, two studies have provided suggestive evidence that very small amounts of Vif may be present in virions (5, 50) . However, these studies did not distinguish between specific and unspecific particle association (e.g., contamination of virus pellets with Vif-containing vesicles). Because the Vif-minus phenotype (abnormal assembly of the viral nucleoprotein core, reduced proviral DNA synthesis upon entry of new cells, and ability to complement Vif in the producer but not the target cell) could also be explained by a more direct role for Vif in virion assembly, morphogenesis, and early infection events, we elected to reexamine the possibility that Vif is a virion-associated protein. Using high-titer Vif-specific antibodies (16) and sensitive immunodetection techniques, we found that Vif is indeed packaged into HIV-1 and SIV SM particles. Incorporation of Vif was specific, occurred in quantities comparable to the viral pol gene products, and was not due to an association with viral surface proteins or the viral membrane. Most importantly, virion subfractionation studies showed that Vif is associated with the purified viral core. These results are in agreement with the phenotypic characteristics of vif-minus viruses, in particular with the reported differences in nucleoprotein core morphology (19) , and raise the possibility of a direct function for Vif in early replication events.
MATERIALS AND METHODS
Cells and viruses. HeLa-tat (HLtat) cultures were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. These cells express the first exon of HIV-1 tat constitutively (9) and were kindly provided by B. Felber and G. Pavlakis. SupT1 and CEMx174 immortalized T-cell lines were maintained in RPMI 1640 medium supplemented with 2 mM Lglutamine, 100 g of gentamicin per ml, and 15% fetal bovine serum (complete medium). Human peripheral blood mononuclear cells (PBMCs) were obtained from healthy adult volunteers by Ficoll-Hypaque density gradient centrifugation as described previously (35) . PBMCs were stimulated with phytohemagglutinin (2 g/ml) for 24 h, washed free of lectin, and maintained in complete medium supplemented with 30 U of interleukin-2 (Boehringer Biologicals) per ml.
Infectious molecular clones of HIV-1 YU-2 (cloned from uncultured human brain; see references 27 and 28 for details), HIV-1 SG3 (cloned from productively infected HUT 78 cells [14] ), and SIV SM PBj1.9 (cloned from short-term-infected PBMC DNA [7] ) have been described elsewhere. Virus derived from HIV-1 SG3 replicates to very high titers both in immortalized T-cell lines and in PBMCs (14) . Virus derived from SIV SM PBj1.9 replicates well in human and macaque PBMCs and causes an acute illness in experimentally infected pigtailed macaques similar to primary HIV-1 infection (20) . Virus derived from HIV-1 YU-2 replicates well in primary lymphocytes and macrophages but not in established T-cell lines (27) . Both SG3 and YU-2 genomes lack a functional vpu gene (YU-2 lacks the vpu initiation codon, and SG3 contains a 23-bp deletion in the vpu open reading frame). The PBj1.9 genome contains uninterrupted open reading frames for all proviral genes.
To obtain a genomically intact YU-2 clone, PCR mutagenesis was performed to reinstate the vpu initiation codon. A 458-bp fragment including the vpu gene was amplified by using a pair of sense (5Ј-TAGTACATGTAATGCAATCTTT ACAAG-3Ј) and antisense (5Ј-CCACATGTTAAAATTTTCTGT-3Ј) primers. The sense primer contained an A at position 5613 (underlined) which restored the vpu initiation codon (CTG to ATG). The mutagenized fragment was reintroduced into the YU-2 provirus, resulting in a proviral clone, termed pYU-2C, which differs from pYU-2 by only a single base pair. This was confirmed by sequence analysis of pYU-2C.
Construction of vif-deficient HIV-1 and SIV SM proviruses. PCR mutagenesis was used to generate a vif-deficient YU-2C provirus. Briefly, a 566-bp (vif-containing) DNA fragment was amplified from pYU-2 by using sense (5Ј-TCACG AGCTCGCACCATATGTAGATTTAAGGGA-3Ј) and antisense (5Ј-AAGCC ATGTAGCCATGGCCTAGGA-3Ј) primers. The sense primer introduced a G (instead of a T) at position 4679 and an A (instead of a C) at position 4684 (underlined), generating two in-frame stop codons within the vif open reading frame at amino acid positions 30 (TAT to TAG) and 32 (TCA to TAA) (Fig.  1A) . The mutagenized fragment was reinserted into the YU-2C genome by using a series of different subcloning steps, generating pYU-2C vifϪ . Site-directed mutagenesis of the SIV SM PBj1.9 vif gene was accomplished by using a Muta-Gene kit (Bio-Rad). Briefly, an internal 4.5-kb EcoRI fragment was excised from the PBj1.9 genome and ligated into pTZ19. An internal BamHISstI (vif-containing) DNA fragment was then subcloned into M13 and mutagenized to abrogate Vif translation. Two mutagenic primers were used. One (antisense, 5Ј-CCACTATCTAATCCTTTTCCTCCTCCGTAGTCTTT-3Ј) introduced a C (instead of a T) at position 5108 and an A (instead of a G) at position 5126; the other (antisense, 5Ј-TTCAGGTGTTAGATGAGGCTA-3Ј) changed an A to a T at position 5185 (Fig. 1B) . These substitutions changed the Met initiation codon to a Thr and introduced in-frame translational stop codons at positions 5125 and 5185. None of the introduced nucleotide substitutions resulted in amino acid changes in the overlapping pol open reading frame (Fig.  1B) . The mutagenized DNA fragment was ligated back into the pTZ19 shuttle vector, and the 4.5-kb EcoRI fragment was the ligated back into the PBj1.9 provirus, generating pPBJ1.9 vifϪ . Both YU-2C and PBj1.9 vif mutations were confirmed by DNA sequence analysis.
Antibodies. Antibodies used in this study included monoclonal antibodies reactive with the p24
Gag protein of HIV-1 (ATC1; obtained from a hybridoma cell line purchased from the American Tissue Culture Collection) and the p27 HIV-2 and SIV SM Vif-specific antibodies were raised against a synthetic oligopeptide. A 21-mer (MEEDKRWIVVPTWRVPGRMEK) corresponding to a region of predicted protein antigenicity in the Vif protein of HIV-2 ROD (coordinates 4869 to 4931 [17] ) was synthesized on a model 430 peptide synthesizer (Applied Biosystems, Inc.). The oligopeptide was coupled to keyhole limpet hemocyanin in a glutaraldehyde single-step coupling procedure and used to immunize New Zealand White female rabbits subcutaneously with 200 g of peptide emulsified in an equal volume of Freund's complete adjuvant. Rabbits were boosted at 2-week intervals with 200 g of coupled peptide mixed with an equal volume of Freund's incomplete adjuvant. Sera were titered by enzymelinked immunosorbent assay (ELISA), using an uncoupled oligopeptide, and collected at peak titers for analysis.
Transfection and virus purification. Transfections of proviral clones were performed on 40 to 60% confluent HLtat cells by the calcium phosphate DNA precipitation method as recommended by the manufacturer (Stratagene). Sixty hours after transfection, culture supernatants were collected, clarified by lowspeed centrifugation (1,000 ϫ g, 10 min), and filtered through a 1.2-m-pore-size filter. Supernatants from productively infected cells were prepared similarly. Virions were concentrated by ultracentrifugation (125,000 ϫ g, 2 h) through 20% sucrose. Viral pellets were solubilized for immunoblot analysis or resuspended in TNE buffer (10 mM Tris-HCl [pH 7.2], 100 mM NaCl, 1 mM EDTA) for sucrose gradient analysis. Sucrose-purified particle preparations were quantified by RT analysis or p24 antigen capture.
Proteinase K digestion of viral surface proteins. Supernatants (360 ml) from SupT1 cells productively infected with HIV-1 SG3 (2.6 ϫ 10 7 RT counts/ml) were pelleted through cushions of 20% sucrose and resuspended in proteinase K . One half of the virus preparation was adjusted with proteinase K (Gibco/BRL) to a final concentration of 1 mg/ml, while the other was diluted with equivalent volumes of digestion buffer. After incubation at 22ЊC for 18 h, the proteinase inhibitor phenylmethylsulfonyl fluoride was added (5 mg/ml, final concentration), and both aliquots were centrifuged again through cushions of 20% sucrose. Lysates of both proteinase-treated and untreated virion preparations were analyzed by immunoblot analysis.
Preparation of viral core structures. Core structures of HIV-1 were prepared by methods previously described for the purification of SIV MAC cores (49) . Briefly, culture supernatants (500 ml) from SupT1 cells productively infected with HIV-1 SG3 (1.4 ϫ 10 7 RT counts/ml) were pelleted through 20% sucrose and dissolved in TNE buffer (800 l) by continuous mixing for 2 h at 4ЊC. To remove the viral membrane, one aliquot (400 l) was treated with Triton X-100 at a final concentration of 0.5% at 20ЊC for 8 min, diluted in TNE, and pelleted through 50% sucrose (to remove any enveloped particles that may have remained). The other aliquot was mock treated in TNE. Both detergent-treated and untreated particle preparations were then diluted with TNE and centrifuged (100,000 ϫ g, 18 h, 4ЊC) over linear gradients of sucrose prepared by mixing equal volumes of 30% (wt/vol) sucrose dissolved in water and 70% (wt/vol) sucrose dissolved in deuterium oxide (Sigma). Fourteen fractions were collected from the bottom of each tube, diluted in phosphate-buffered saline (PBS), pelleted by ultracentrifugation, and examined for protein content by immunoblot analysis. The density of each fraction was determined with a refractometer.
Western blot (immunoblot) analysis. Virions were concentrated from the supernatants of transfected or infected cells by ultracentrifugation through 20% sucrose (125,000 ϫ g, 2 h, 4ЊC). Infected cells and virus pellets were solubilized in loading buffer (62.5 mM Tris-HCl [pH 6.8], 0.2% sodium lauryl sulfate [SDS], 5% 2-mercaptoethanol, 10% glycerol), boiled for 5 min, and separated on 12.5% polyacrylamide gels containing SDS. Following electrophoresis, proteins were transferred to nitrocellulose (0.2-m pore size; Schleicher & Schuell) by electroblotting, incubated for 1 h at room temperature in blocking buffer (5% nonfat dry milk in PBS), and then incubated for 2 h with the appropriate antibodies diluted in blocking buffer (the anti-HIV-1 Vif antiserum was used at a dilution of 1:1,000; the anti-SIV SM Vif antiserum was used at a dilution of 1:100). Protein bound antibodies were detected with horseradish peroxidase-conjugated specific secondary antibodies, washed extensively, and developed by using the highly sensitive ECL (enhanced chemiluminescence) detection system (Amersham).
Quantitation of virion-associated Vif protein. Dilution panels (external standards) were prepared from two different sources of recombinant Vif protein, including a histidine-tagged, nickel column-purified recombinant Vif protein provided by Dana Gabudzda (11) and a commercially available preparation of Escherichia coli-expressed Vif obtained from Intracel (Cambridge, Mass.). Also used as an external standard was a dilution panel of highly purified p51 RT protein (provided by Jacob Lebowitz [25] ). Protein concentrations and purity (Ͼ95%) were confirmed in two independent laboratories. SG3 virions were produced by SupT1 cells, banded on a 20 to 60% linear gradient of sucrose, and quantitated by p24 antigen capture ELISA (Coulter, Hialeah, Fla.). Western blot band intensities were determined on a Lynx 5000 molecular biology work station with matched custom software (Applied Imaging, Santa Clara, Calif.).
RESULTS

Detection of Vif protein in HIV-1 particles.
Concentrated preparations of HIV-1 virions were prepared from SupT1 cells productively infected with HIV-1 SG3 . We chose this particular strain of HIV-1, since it replicates to high titers in both PBMCs and immortalized T-cell lines (14) . HIV-1 SG3 proviral DNA (pSG3) was transfected into HLtat cells, and infectious virus was transmitted to SupT1 cells by cocultivation. Virus replication was monitored by RT analysis, and at peak titers (2 ϫ 10 7 cpm of RT activity per ml), culture supernatants were collected and clarified by low-speed centrifugation (1,000 ϫ g, 15 min). Virus was then concentrated by ultracentrifugation through 20% sucrose (125,000 ϫ g, 2 h, 4ЊC), resuspended in electrophoresis buffer, and examined for the presence of Vif and Gag proteins by immunoblot analysis. Infected cell lysates were analyzed in parallel. Using an anti-Vif antibody raised against bacterially expressed HXB2 Vif protein (16) and the highly sensitive ECL detection method, we detected a 23-kDa protein in both infected cells and purified virions (Fig. 2A) . Gag proteins were detected in cell and viral lysates with an anti-p24 Gag monoclonal antibody ( Fig. 2B ; the lanes probed with the antiVif antibody contain five times more lysate than those probed with anti-Gag antibody). These results demonstrated the presence of a 23-kDa Vif-reactive protein in infected cell lysates and sucrose-purified HIV-1 particles and suggested that the relative proportion of cell-associated Vif packaged into virions was less than that of p24 Gag . To confirm that Vif was indeed packaged into HIV-1 virions and not just simply cosedimenting with the pelleted material, immunoblots were performed on banded virus preparations collected from continuous sucrose density gradients. For these experiments, HIV-1 SG3 virions were pelleted from supernatants (50 ml) of infected SupT1 cultures (3 ϫ 10 7 cpm of RT activity per ml), resuspended in 800 l of PBS, loaded onto continuous gradients of 20 to 60% sucrose, and centrifuged overnight (100,000 ϫ g, 18 h, 4ЊC). Fractions were collected, concentrated by ultracentrifugation (125,000 ϫ g; 1 h), and analyzed by immunoblotting (Fig. 3) . Replica blots were probed independently with anti-Gag (Fig. 3A) and anti-Vif (Fig. 3B) antibodies. The results demonstrated peak concentrations of both Gag and Vif proteins in the same fractions at a specific gravity of 1.17 g/ml, suggesting a direct association of Vif protein with virus particles.
Detection of Vif protein in HIV-1 virions derived from permissive and nonpermissive producer cells. To examine whether the association of Vif protein with virions was influenced by the cells in which the virus was propagated, three different cell types were used to produce infectious HIV-1 SG3 . At peak levels of virus replication (as determined by RT assay), virions were concentrated from the culture supernatants of infected phytohemagglutinin-stimulated normal human PBMCs and SupT1 cells, and transfected HLtat cells by ultracentrifugation through 20% sucrose. Pellets were lysed, and equal concentrations of virions (RT equivalents) were examined by immunoblot analysis (Fig. 4) . Vif protein was detected in similar quantities in viral pellets derived from permissive HLtat cultures, semipermissive SupT1 cultures, and nonpermissive PBMC cultures (Fig. 4A) . Similar amounts of p24 Gag were detected for all virus preparations ( Fig. 4B ; the lanes probed with the antiVif-antibody contain five times more viral lysate than those probed with the anti-Gag antibody). These results indicate that Vif protein is incorporated into virions in similar amounts relative to Gag, independent of the producing cell type.
Incorporation of Vif protein into virions derived from different HIV-1 strains. Our results indicated efficient incorporation of Vif protein into HIV-1 SG3 virions. Since this provirus was cloned after continuous passage in an established T-cell line and contains a defective vpu gene (14) , we wanted to confirm virion association of Vif in a second, biologically relevant virus strain. The YU-2C strain was thus selected for comparison, since it was cloned without interim tissue culture directly from infected human brain (27, 28) and since it contains a complete set of accessory genes after restoration of its vpu initiation codon (see Materials and Methods). For control, a vif-deficient mutant of YU-2C and wild-type SG3 were analyzed in parallel. Proviruses were transfected into HLtat cells, supernatant was collected 60 h later, and virions were examined by immunoblot analysis following concentration through 20% sucrose cushions (Fig. 5) . Replica blots were probed separately with anti-Vif (Fig. 5A ) and anti-Gag (Fig. 5B) antibodies. Vif protein was detected in pellets derived from pYU-2C and SG3 but not in similarly prepared pellets of pYU-2C vifϪ . Similar amounts of Gag protein were detected for the three different viruses, confirming equivalent numbers of particles (Fig. 5B) . These results indicate that different strains of HIV-1, including viruses present in vivo, package Vif in similar quantities.
Detection of Vif protein in SIV SM virions. The vif gene is conserved in all primate lentiviral lineages, and its function is thought to be similar to that of HIV-1 (30, 32, 33, 38) . To determine whether the Vif protein of HIV-2 and SIV SM strains is also incorporated into virions, we examined wild-type and vif-deficient SIV SM PBj1.9 particles. Proviral DNAs were transfected into HLtat cells, and progeny virions were pelleted through sucrose cushions and examined by immunoblot analysis. Transfection-derived preparations of wild-type and vifminus PBj1.9 were also transmitted to CEMx174 cells, propagated to high titers, and concentrated for immunoblot analysis (Fig. 6) . Replica blots were probed with a Vif-specific antibody raised against a synthetic oligopeptide and a monoclonal antibody reactive with HIV-2 Gag (Fig. 6) . A 27-kDa protein was detected in viral pellets of wild-type PBj1.9 derived from both HLtat (Fig. 6A) and CEMx174 (Fig. 6B ) cells but not in virions produced from vif-mutant PBj1.9. Comparable amounts of p27 Gag antigen confirmed equivalent amounts of wild-type and mutant viruses. These results suggest that the ability to package Vif protein is a general property of primate lentiviruses.
Association of HIV-1 Vif protein with viral core structures. To exclude the possibility that Vif might nonspecifically adsorb FIG. 3 . Vif protein content of particles purified by sedimentation over continuous sucrose gradients. HIV-1 SG3 virions were concentrated from supernatants (50 ml) of productively infected SupT1 cells (3 ϫ 10 7 RT counts per ml) by ultracentrifugation through 20% sucrose. Pellets were resuspended in PBS, layered over a 20 to 60% linear gradient of sucrose, and centrifuged for 18 h at 100,000 ϫ g in an SW41 Beckman rotor. Fractions (0.5 ml) were collected from the bottom of the tube, diluted, pelleted a second time by ultracentrifugation in a TL45 Beckman rotor (125,000 ϫ g, 1 h, at 4ЊC), and lysed in electrophoresis buffer for immunoblot analysis. Replica blot were probed separately with antiGag (A) and anti-Vif (B) antibodies. Fraction 2 represent the second collection from the bottom of the gradient, and fraction 22 represents the last. (C) Fractions were also analyzed for density with a refractometer. to the outer surface of HIV-1 virions, we determined its subvirion localization. HIV-1 SG3 virions, derived from productively infected SupT1 cultures, were pelleted through 20% sucrose and resuspended in proteinase digestion buffer, and one half of the preparation was treated with proteinase K (final concentration of 1 mg/ml). Because HIV-1 particles contain a lipid bilayer, structural components inside this membrane are protected from proteolytic digestion, whereas those on the outer surface such as gp120 or the exterior portion of gp41 are not. Following incubation at 22ЊC for 18 h, virions were treated with a protease inhibitor (phenylmethylsulfonyl fluoride; 5 mg/ ml), pelleted through 20% sucrose, and lysed for immunoblot analysis. Non-proteinase K-treated SG3 particles were prepared in parallel. The protein profiles of treated and untreated virions, analyzed on replica blots with anti-Vif, anti-p24
Gag , and anti-gp41 antibodies, are depicted in Fig. 7 .
The viral transmembrane protein, gp41, was detected in untreated but not in proteinase K-treated virions (Fig. 7C) . Since the monoclonal antibody used in this experiment reacts with an epitope on the exterior portion of gp41 (34, 48) , these results indicated that proteinase K digestion had indeed removed proteins from the surface of virions. As expected, antip24
Gag antibodies detected Gag proteins in both treated and untreated preparations with comparable intensities (Fig. 7B) . This result confirmed the integrity of the proteinase K-treated virions and indicated that blots contained equivalent numbers of particles. Finally, anti-Vif antibodies detected similar quantities of Vif protein in both treated and untreated preparations (Fig. 7A ). This result suggested that Vif (like Gag) is protected from proteinase K digestion and must therefore be located inside the viral envelope.
To further explore the localization of Vif within the HIV-1 particle and to exclude the possibility that Vif-containing vesicles could copurify with virions, we examined whether Vif protein would remain particle associated after solubilization of the virion lipid bilayer. HIV-1 SG3 was propagated in SupT1 cells and concentrated from 500 ml of culture supernatants at peak virus production (1.4 ϫ 10 7 RT counts/ml). Pelleted virions were resuspended in TNE and treated with Triton X-100 at a final concentration of 0.5% for 8 min at room temperature. Virus was then separated into two equal aliquots. One aliquot was centrifuged (125,000 ϫ g, 2 h) through 20% sucrose, while the other was centrifuged similarly through 50% sucrose. For controls, equal amounts (as determined by RT activity) of non-Triton X-100-treated virions were prepared in parallel. Following centrifugation, viral pellets were solubilized in electrophoresis buffer and examined for differences in their protein profiles by using anti-Vif, anti-p24 Gag , anti-RT, and antip17 Gag (matrix) antibodies. Figure 8A depicts replica blots of detergent-treated and untreated virions following centrifugation through 20% sucrose. The results revealed virtually identical Vif, RT, and Gag reactivities, indicating similar quantities of each of these proteins in wild-type and membrane-denuded core structures. By contrast, matrix protein reactivity was significantly reduced in Triton X-100-treated virions, suggesting that removal of the viral membrane had led to the partial removal of the submembrane matrix protein as well. This inference was further confirmed by analysis of immunoblots prepared following centrifugation through cushions of 50% sucrose, which enriches for viral core structures relative to enveloped particles (Fig. 8B) . Enveloped HIV-1 virions sediment in sucrose gradients at 1.15 to 1.17 g/ml, while viral cores are much denser and sediment at approximately 1.25 g/ml (49) . Accordingly, centrifugation through 50% sucrose resulted in a significant loss of Vif, Gag, and RT reactivities in untreated virions but not in detergenttreated virions, which, because of their higher density, pelleted to the bottom of the tube (Fig. 8B) .
As a final confirmation of the association of Vif with viral core structures, Vif protein content of Triton X-100-treated virions banded over continuous sucrose gradients was determined. SG3 virions were concentrated from culture supernatants of infected SupT1 cells as described above, treated with Triton X-100, pelleted through 50% sucrose to enrich for core HIV-1 SG3 virions were collected from the culture supernatants of SupT1 cells and pelleted through 20% sucrose. Pellets were resuspended in TNE buffer and aliquoted into two tubes. One aliquot was treated with 0.5% Triton X-100 (ϩ) at 20ЊC for 8 min; for control, the other was not treated (Ϫ). Each aliquot was separated into two tubes and centrifuged over 20% (A) or 50% (B) sucrose. Pellets were lysed and examined by immunoblot analysis. Replica blots were probed with anti-Vif, anti-Gag, anti-RT, and anti-matrix (MA) antibodies. structures, and centrifuged (100,000 ϫ g, 18 h, 4ЊC) through a linear gradient of 30 to 70% sucrose dissolved in deuterium oxide to ensure solubility. Identical quantities of untreated SG3 virions were analyzed in parallel. Fractions were collected, diluted in TNE, and centrifuged again to concentrate virions. Pellets were solubilized and examined by immunoblot analysis (Fig. 9) . Replica blots were probed separately with anti-Vif, anti-Gag, and anti-RT antibodies. For untreated virions, peak concentrations of Gag and RT proteins were detected in fractions 10 and 11 (Fig. 9A ), corresponding to a density of 1.15 to 1.16 g/ml. For detergent-treated virions, peak concentrations of Gag and RT shifted closer to the bottom of the gradient (fractions 5 and 6), corresponding to a density of 1.24 to 1.25 g/ml. This result confirmed that Triton X-100 treatment had resulted in the removal of the viral envelope and that Vif protein colocalized with Gag and RT proteins in purified HIV-1 core structures.
Quantitation of Vif protein in virions. To determine how much Vif was packaged into HIV-1 particles, we prepared dilution panels of recombinant Vif protein and used them as external standards to quantify Vif in sucrose-banded virion preparations by Western blot analysis (Fig. 10) . We used two independent recombinant Vif protein preparations, which gave virtually identical results (Fig. 10B depicts results obtained with prokaryotically expressed Vif kindly provided by Dana Gabuzda). Their concentrations and purity (Ͼ95% by Coomassie blue gel staining) were confirmed. HIV-1 SG3 virions were derived from productively infected SupT1 cultures, banded on a 20 to 60% linear gradient of sucrose, and quantified by p24 antigen capture ELISA (Coulter). Virions from a single gradient fraction (at peak p24 concentration) were then used for all subsequent Western blot analyses (Fig. 10) .
Both sucrose-banded SG3 virions and recombinant Vif protein were serially diluted, run on the same SDS-polyacrylamide gel, and electroblotted onto nitrocellulose (Fig. 10A) . Following probing with an anti-Vif antibody, immunoblot intensities of the Vif dilution panel (ranging from 0.3 to 10 ng of purified Vif) were quantified on a Lynx densitometer (Applied Imaging) and used to plot a standard curve (Fig. 10B) . This graph was then used to determine the amount of Vif protein present in different dilutions of sucrose-banded virions. Using only values within the linear signal range of the ECL detection system, we determined that 4.3, 1.7, and 0.8 ng of Vif correspond to 100, 50, and 25 ng of virion-associated p24 Gag, respectively (Fig. 10B) . Since Vif and p24 have similar molecular weights, these values indicate a packaging ratio of 20 to 30 molecules of p24 Gag for each molecule of Vif, or between 60 to 100 molecules of Vif per virus particle (assuming approximately 2,000 molecules of p24 per virion [2, 24] ).
Because our estimates of virion-associated Vif protein were higher than a previous suggestion (50), we sought to validate our experimental approach by quantifying an HIV-1 protein of FIG. 9 . Sucrose gradient analysis of HIV-1 virions treated with Triton X-100. HIV-1 SG3 virions were collected from the culture supernatants of SupT1 cells and pelleted through cushions of 20% sucrose. Pellets were resuspended in TNE buffer and aliquoted into two tubes. One aliquot was treated with 0.5% (final concentration) Triton X-100 at 20ЊC for 8 min and then centrifuged through 50% sucrose to enrich for viral core structures. The other aliquot was mock treated for control. Both untreated (A and C) and treated (B and D) preparations were centrifuged (100,000 ϫ g, 18 h, 4ЊC) over linear gradients of sucrose prepared by mixing 4 ml of 30% (wt/vol) sucrose in water with 4 ml of 70% (wt/vol) sucrose in deuterium oxide (Sigma). Fourteen fractions were collected from the bottom of each tube. Each fraction was diluted with PBS, pelleted again in a Beckman TL45 rotor, and examined by immunoblot analysis (A and B). Replica blots were probed with anti-Vif, anti-Gag, and anti-RT antibodies. Sucrose fractions were also analyzed for density with a refractometer (C and D).
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known virion content, RT (Fig. 10C) . Using a dilution panel of purified recombinant RT (p51 RT [25] ), we determined that 4.2, 3.0, and 1.7 ng of p51 RT correspond to 50, 25, and 12.5 ng of particle-associated p24 Gag, respectively (standard curve not shown). Calculating the corresponding numbers of RT and p24 molecules (assuming p51-p66 heterodimers), we determined a ratio of 10 to 20 molecules of p24 Gag for each molecule of RT. These results are in excellent agreement with previously reported estimates of particle-associated RT (24, 31) , thereby corroborating our quantitative determinations of Vif. Sucrose-banded SG3 virions were also probed with an anti-Gag antibody (Fig. 10D ), which confirmed a normal protein profile with respect to processed and unprocessed Gag proteins. Taken together, these results indicate that Vif is packaged into HIV-1 particles in quantities comparable to (or slightly less than) those of the viral pol gene products.
DISCUSSION
Vif is known to influence the replication potential of HIV and SIV by enhancing viral infectivity (10, 12, 13, 23, 32, 33, 36, 37, 39, 42) . Since earlier reports failed to demonstrate its presence in the virus particle (37, 45) , it has been proposed that Vif affects viral infectivity indirectly through its actions on virion assembly, release, and/or maturation (5, 6) . Accordingly, particles assembled in the absence of Vif are believed to be noninfectious because their structural proteins have been either not properly modified before budding from the producer cell or not processed normally subsequent to budding and extracellular release. Because the Vif-minus phenotype could also be due to the absence of Vif from virus particles, we reexamined the possibility that Vif is a virion-associated protein. To increase our chances for Vif detection, we used hightiter Vif-specific antibodies (16), highly concentrated virion preparations (generally on the order of 50 to 200 ng of particleassociated p24 antigen per immunoblot), and the ECL immunoblot detection method, which is at least 10 times more sensitive than most other conventional methods. Using these optimized conditions, we were able to reproducibly detect Vif protein in cell-free virion preparations of two different primate lentiviruses (HIV-1 and SIV SM ). The virion-associated HIV-1 and SIV SM Vif proteins were identical in size to their cellular counterparts (23 and 27 kDa, respectively), suggesting that packaging did not result in (or require) protein processing. In addition, the presence of Vif in virions was not the property of any particular virus strain or dependent on the type of producer cell. Comparison of the Vif content in HIV-1 SG3 (vpuminus) and HIV-1 YU-2C (vpu-plus) indicated that vpu was not required for Vif packaging. Finally, the amount of virion associated Vif protein was estimated to be on the order of 1 Vif molecule per 20 to 30 molecules of p24 Gag, or 60 to 100 molecules per particle.
Because the presence of Vif protein in concentrated virions could have been the result of unspecific adsorption to the viral envelope, we performed virion fractionation studies to exclude this possibility. In a first step, virions were treated with proteinase K to remove surface proteins. To control for this process, we used an antibody specific for an external epitope of gp41 (34, 48) . As expected, no gp41 reactivity was detectable in treated virions, while the same protein was readily visible on blots of untreated virus. By contrast, no differences in Gag and Vif reactivities were observed on immunoblots of the same virus preparations. These results suggested that Vif (like Gag) was protected from proteolytic digestion because it is located internal to the viral membrane. Since Vif has been reported to associate with the inner surface of the lipid bilayer (16), we also considered that Vif may have been detected in association with virions because it was present in the viral membrane. Moreover, the presence of Vif in viral pellets could be explained by cosedimentation of Vif-containing cell-derived vesicles or micelles. We thus treated concentrated virions with a mild detergent (Triton X-100) to disrupt the viral membrane (and membranes of any copurifying vesicles) and isolated viral core structures following centrifugation through sucrose. Using a methodology previously employed to determine the virion sublocalization of Vpx in SIV MAC (49), we were able to titrate the detergent treatment such that the lipid bilayer of most particles could be removed without concomitant destruction of the remainder of the particle. Western blot analysis revealed significantly lower quantities of p17
Gag in virions treated with Triton X-100. However, Vif protein content (like that of p24 and RT) was unaffected by the removal of the viral membrane and submembrane matrix protein. This was also the case following centrifugation through 50% sucrose which, due to their greater density, selectively enriched for viral core structures. Particle association of Vif was further confirmed by analysis of detergent-treated and untreated virions on linear sucrose gradients. Enveloped virions sedimented at the expected density of 1.15 to 1.17 g/ml as determined by peak Gag and RT concentrations. By contrast, detergent-treated core structures sedimented at a much higher density of 1.25 g/ml. Importantly, in both instances Vif protein cosedimented with maximal Gag and RT reactivities. Taken together, these results indicate that Vif represents an integral component of the virus core and that within the virus particle, the majority of Vif protein is not associated with the viral membrane or submembrane compartments.
Given the intensities of Vif protein on immunoblots (compare Fig. 2 to 9) , it is somewhat surprising that the presence of Vif in virions has not been reported earlier. Two technical factors may explain this circumstance. One is the choice of antibodies. Clearly, not all antibodies that detect cell-associated or bacterially expressed Vif protein can detect Vif in the virus particle (37) . For example, we failed to detect virionassociated Vif protein with a different anti-HIV-1 Vif antibody from the NIAID Repository (data not shown). Similarly, our anti-SIV SM Vif antibody was much less active and required up to 100-fold more virion RT equivalents to yield a positive Western blot. The second factor relates to the amount of virus particles analyzed per immunoblot. We used highly concentrated HIV-1 preparations, on the order of 50 to 200 ng of particle-associated p24 per lane. Most previous studies, including those that failed to detect Vif in virions (37, 44) , did not specify how many particles were analyzed.
Zombeck et al. were the first to describe an association of Vif with the HIV-1 virion (50). However, these investigators found only very small quantities (i.e., 5 to 15 molecules) of Vif per particle, leading them to conclude that the packaging of Vif was likely unspecific and thus of questionable biological relevance. Our estimate of virion-associated Vif is nearly 1 order of magnitude higher and on the order of quantities described for the viral pol gene products. It should be emphasized that we used a number of controls to derive these values. First, all quantitation was performed in the linear range of the ECL detection system (Fig. 10B) . Second, the anti-Vif antibody used for quantitation in Fig. 10 was raised against the same Vif protein included as the external standard (11) . Third, a second dilution panel prepared from commercially available Vif protein yielded virtually identical results (data not shown). Fourth, simultaneous use of highly purified p51 RT protein as an external standard confirmed the reliability our assay system. Fifth, signal intensities of external standards and virion preparations were always compared on the same immunoblot. Thus, our estimate of virion-associated Vif protein should be accurate, at least within the limitations of the assay system. In addition, it should be noted that our findings have most recently been confirmed by other investigators (22) . Coexpressing an epitope-tagged Vif protein with a vif-deficient HIV-1 provirus, Karczewski and Strebel identified Vif protein in the viral core in readily detectable quantities (22) . Moreover, these investigators also report an association between Vif and p24 Gag, as evidenced by coimmunoprecipitation of both proteins. Although this may suggest how Vif is packaged, additional experiments are necessary to determine whether Vif is incorporated into the HIV-1 particle by a specific mechanism.
Although there is currently no formal proof that the presence of Vif in the particle has functional consequences, evidence is increasing that the virion association of Vif is important for early replication events. Vif-mutant virus produced by nonpermissive cells is characterized by an abnormal ultrastructural morphology and protein composition (5, 19) . The structure of the nucleoprotein core in particular seems to be altered in the absence of Vif, exhibiting nonhomogeneous packing or redistribution of electrodense material (19) . It is thus possible that a direct interaction of Vif with either Gag or Gag/Pol precursor molecules before, during, and/or after budding is necessary for their proper folding, assembly, and/or processing. As a core protein, Vif may also associate with the preintegration complex and facilitate (either directly or indirectly) its nuclear transport upon internalization into new target cells. The recent finding that Vif interacts with the cellular cytoskeletal network further supports this possibility (22) . Finally, as a virion component, Vif may also affect proviral DNA synthesis by interacting with the RT, the NC protein, or the viral RNA. Whatever its exact mechanism of action may be, it will be important to determine whether incorporation of Vif into virions is of functional relevance. Given the absolute requirement of Vif for virus replication in natural target cells, inhibition of its incorporation into virions could represent a new therapeutic strategy against HIV.
